Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
CSA Medical Inc., a developer of medical devices advancing the power of liquid nitrogen spray cryotherapy, today announced its 500th Metered...
CSA Medical, Inc., today announced results from the first randomized, controlled study of Metered Cryospray (MCS) utilizing the RejuvenAir® System...
CSA Medical, Inc., today announced that all subjects have been enrolled in the RejuvenAir® System study Characterizing the Mechanism of Action of...
CSA Medical, Inc., today announced that Wissam Abouzgheib, MD, chief of pulmonary medicine at Cooper University Health Care, Camden, New Jersey, has...
CSA Medical, Inc., today announced metered cryospray utilizing the RejuvenAir® System for the treatment of Chronic Bronchitis was featured in...
CSA Medical, Inc., today announced that over half of the subjects in a 32 patient study, characterizing the mechanism of action of Metered Cryospray...
CSA Medical Inc., a developer of medical devices advancing the power of liquid nitrogen spray cryotherapy, today announced the first patient treated...
CSA Medical, Inc., presented positive 12-month results of its feasibility study for the RejuvenAir Metered Cryospray™ system yesterday at the 2019...
CSA Medical today announced the presentation of three clinical abstracts highlighting truFreeze® Spray Cryotherapy for treatment of Barrett's...
CSA Medical today announced the presentation of two clinical abstracts highlighting the safety and efficacy of truFreeze® Spray Cryotherapy for...
CSA Medical today announced that the company's truFreeze® Spray Cryotherapy will be featured in five sessions at Digestive Disease Week® (DDW®) 2019. ...
CSA Medical announced the first live case highlighting the use of the company's truFreeze® Spray Cryotherapy in a patient with esophageal cancer that ...
CSA Medical Inc. presented positive results of its feasibility study of the RejuvenAir® Metered Cryospray™ system at the 2018 European Respiratory...
CSA Medical, Inc. is pleased to announce the presentation of key findings related to truFreeze® Spray Cryotherapy at this year's Digestive Disease...
April is Esophageal Cancer Awareness month. CSA Medical is committed to raising awareness of Esophageal Cancer and the importance of early diagnosis...
CSA Medical, Inc. announced the completion of the treatment phase for its ongoing study The Safety and Feasibility Study of RejuvenAir for Treating...
CSA Medical is pleased to announce that in a multi-center prospective study conducted at three leading academic centers published in the Journal of...
CSA Medical, Inc, has appointed Jean Bjerke, MBA as Vice President of Marketing. In this role, Ms. Bjerke will have the responsibility of developing...
CSA Medical announced on Thursday, the expansion of its truFreeze® label to refer specifically to Barrett's Esophagus with high grade dysplasia. This ...
CSA Medical today announced new clinical data related to its truFreeze® Spray Cryotherapy (SCT) system to be presented in a series of oral and poster ...
CSA Medical, Inc., a company focused on developing spray cryotherapy devices that selectively freeze and ablate unwanted tissue inside the body,...
CSA Medical today announced the initial use of a modified cryogen decompression tube (CDT) during a truFreeze Spray Cryotherapy (SCT) case at...
CSA Medical held a mini-symposium at the ERS Conference on Tuesday, September 6, 2016 in London, England. The symposium highlighted early data from...
CSA Medical announces its upcoming mini-symposium at the ERS Conference, taking place on Tuesday, September 6, 2016 in London, England. The symposium ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.